These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 16230089)

  • 1. Steroids in the management of PBC: why do we need them?
    Blendis L
    Gastroenterology; 2005 Oct; 129(4):1350-2. PubMed ID: 16230089
    [No Abstract]   [Full Text] [Related]  

  • 2. [Autoimmune cholestasis syndrome. Ursodeoxycholic acid is the drug standard].
    Stiefelhagen P
    MMW Fortschr Med; 2007 May; 149(21):49. PubMed ID: 17668736
    [No Abstract]   [Full Text] [Related]  

  • 3. [Budesonide in treatment of patients with cross primary biliary cirrhosis and autoimmune hepatitis].
    Golovanova EV; Khomeriki SG; Petrakov AV; Serova TI
    Eksp Klin Gastroenterol; 2010; (8):113-7. PubMed ID: 21268335
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of primary biliary cirrhosis with ursodeoxycholic acid, budesonide and fibrates.
    Poupon R
    Dig Dis; 2011; 29(1):85-8. PubMed ID: 21691111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnosis and therapy of primary biliary cirrhosis and primary sclerosing cholangitis].
    Stiehl A
    Z Gastroenterol; 2002 Dec; 40 Suppl 2():29-30. PubMed ID: 12467002
    [No Abstract]   [Full Text] [Related]  

  • 6. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
    Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
    Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Infrequent but serious: autoimmune hepatitis and primary biliary cirrhosis. Early therapy improves long-term prognosis].
    MMW Fortschr Med; 2008 Apr; 150(15):45. PubMed ID: 18510120
    [No Abstract]   [Full Text] [Related]  

  • 8. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial.
    Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Pikkarainen P; Nuutinen H; Färkkilä M
    Hepatology; 2005 Apr; 41(4):747-52. PubMed ID: 15754377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholic acid therapy in primary biliary cirrhosis.
    Podda M; Crosignani A; Battezzati PM; Quagliuolo M; Valsania C; Invernizzi P; Zuin M
    Ital J Gastroenterol; 1996; 28(2):114-7. PubMed ID: 8782007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
    Shi J; Wu C; Lin Y; Chen YX; Zhu L; Xie WF
    Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reflections on therapeutic trials in primary biliary cirrhosis.
    Combes B
    Hepatology; 2005 Nov; 42(5):1009. PubMed ID: 16250047
    [No Abstract]   [Full Text] [Related]  

  • 12. Patients and patience: the pitfalls of primary biliary cirrhosis trials.
    Mayo MJ
    Nat Clin Pract Gastroenterol Hepatol; 2005 Dec; 2(12):552-3. PubMed ID: 16327817
    [No Abstract]   [Full Text] [Related]  

  • 13. Advances in pharmacotherapy for primary biliary cirrhosis.
    Mousa HS; Lleo A; Invernizzi P; Bowlus CL; Gershwin ME
    Expert Opin Pharmacother; 2015 Apr; 16(5):633-43. PubMed ID: 25543678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antifibrotic therapy of liver cirrhosis, with special reference to primary biliary cirrhosis: promises and limitations.
    Jansen PL
    Neth J Med; 1992 Apr; 40(3-4):209-14. PubMed ID: 1603214
    [No Abstract]   [Full Text] [Related]  

  • 15. Management of autoimmune and cholestatic liver disorders.
    Krok KL; Munoz SJ
    Clin Liver Dis; 2009 May; 13(2):295-316. PubMed ID: 19442920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.
    Silveira MG; Lindor KD
    Clin Liver Dis; 2008 May; 12(2):425-43; x-xi. PubMed ID: 18456189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of ursodeoxycholic acid in primary biliary cirrhosis.
    Pham NT; Hart LL
    Ann Pharmacother; 1993 Dec; 27(12):1472-4. PubMed ID: 8305782
    [No Abstract]   [Full Text] [Related]  

  • 18. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid.
    Kurihara T; Niimi A; Maeda A; Shigemoto M; Yamashita K
    Am J Gastroenterol; 2000 Oct; 95(10):2990-2. PubMed ID: 11051391
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis.
    Rautiainen H; Färkkilä M; Neuvonen M; Sane T; Karvonen AL; Nurmi H; Kärkkäinen P; Neuvonen PJ; Backman JT
    Aliment Pharmacol Ther; 2006 Dec; 24(11-12):1545-52. PubMed ID: 17206943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
    Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
    Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.